Konruns Pharmaceutical
Launch date
Employees
Market cap
CAD621m
Enterprise valuation
CAD525m (Public information from Sep 2024)
Share price
CNY20.42 603590.SS
Qinghe Village Beijing (HQ)
Financials
Estimates*
| CNY | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 809m | 810m | 867m | 920m | 1.1b | 1.3b | 1.6b |
| % growth | (24 %) | - | 7 % | 6 % | 17 % | 19 % | 21 % |
| EBITDA | 236m | 226m | 186m | 188m | 323m | 386m | 464m |
| % EBITDA margin | 29 % | 28 % | 21 % | 20 % | 30 % | 30 % | 30 % |
| Profit | 183m | 148m | 101m | 150m | 186m | 235m | 295m |
| % profit margin | 23 % | 18 % | 12 % | 16 % | 17 % | 18 % | 19 % |
| EV / revenue | - | 6.3x | 4.5x | 6.5x | 3.4x | 2.8x | 2.3x |
| EV / EBITDA | - | 22.5x | 20.9x | 31.6x | 11.2x | 9.4x | 7.8x |
| R&D budget | 93.1m | 102m | 86.8m | 94.9m | - | - | - |
| R&D % of revenue | 12 % | 13 % | 10 % | 10 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
| Total Funding | - | ||
